Benchmark Reiterates Buy on Surgery Partners, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bill Sutherland has reiterated a 'Buy' rating on Surgery Partners (NASDAQ:SGRY) and maintained a price target of $50.
July 31, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Bill Sutherland has reiterated a 'Buy' rating on Surgery Partners and maintained a price target of $50.
The reiteration of a 'Buy' rating by a Benchmark analyst and the maintenance of a $50 price target could potentially boost investor confidence in Surgery Partners, leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100